Works matching DE "VEMURAFENIB"

Results: 135

Csecsemőkori multiszisztémás Langerhans-sejtes histiocytosis esete.

Published in:

Gyermekgyógyászat, 2025, v. 76, n. 4, p. 290

By:

Ágnes, Sipkó;
Ágnes, Kelemen;
Erzsébet, Szakos;
Károly, Halász;
Cecília, Ormay

Publication type:

Article

Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University.

Published in:

Pathology & Oncology Research, 2023, p. 1, doi. 10.3389/pore.2023.1611378

By:

Ferenczi, Kata;
Nagy, Zsófia Flóra;
Istenes, Ildikó;
Eid, Hanna;
Bödör, Csaba;
Timár, Botond;
Demeter, Judit

Publication type:

Article

Suppression of exosomal hsa_circ_0001005 eliminates the Vemurafenib resistance of melanoma.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 9, p. 5921, doi. 10.1007/s00432-022-04434-y

By:

Wang, Xicheng;
Cheng, Qiong

Publication type:

Article

A Comprehensive In Silico Exploration of Pharmacological Properties, Bioactivities, Molecular Docking, and Anticancer Potential of Vieloplain F from Xylopia vielana Targeting B-Raf Kinase.

Published in:

Molecules, 2022, v. 27, n. 3, p. 917, doi. 10.3390/molecules27030917

By:

Hassan, Syed Shams ul;
Abbas, Syed Qamar;
Ali, Fawad;
Ishaq, Muhammad;
Bano, Iqra;
Hassan, Mubashir;
Jin, Hui-Zi;
Bungau, Simona G.

Publication type:

Article

Computational Study on the Mechanism of the Photouncaging Reaction of Vemurafenib: Toward an Enhanced Photoprotection Approach for Photosensitive Drugs.

Published in:

Molecules, 2021, v. 26, n. 7, p. 1846, doi. 10.3390/molecules26071846

By:

Bani-Yaseen, Abdulilah Dawoud;
Costa Cabral, Benedito José

Publication type:

Article

Preparation and characterization of vemurafenib microemulsion based hydrogel using surface active ionic liquid.

Published in:

Pharmacia (0428-0296), 2024, v. 71, n. 1, p. 1, doi. 10.3897/pharmacia.71.e111178

By:

Neamah, Mohammed Jasim;
Muhammed Al-Akkam, Entidhar Jasim

Publication type:

Article

Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics.

Published in:

Cancer Biology & Medicine, 2019, v. 16, n. 2, p. 247, doi. 10.20892/j.issn.2095-3941.2018.0375

By:

Grahovac, Jelena;
Srdić-Rajić, Tatjana;
Santibañez, Juan Francisco;
Pavlović, Marijana;
Čavić, Milena;
Radulović, Siniša

Publication type:

Article

SERPINB8 and furin regulate ITGAX expression and affect the proliferation and invasion of melanoma cells.

Published in:

Experimental Dermatology, 2023, v. 32, n. 1, p. 24, doi. 10.1111/exd.14677

By:

Ni, Li;
Li, Pin;
Li, Mingming;
Huang, Shuhong;
Dang, Ningning

Publication type:

Article

BRAF-Inhibitor-Induced Metabolic Alterations in A375 Melanoma Cells.

Published in:

Metabolites (2218-1989), 2021, v. 11, n. 11, p. 777, doi. 10.3390/metabo11110777

By:

Karki, Prashant;
Sensenbach, Shayne;
Angardi, Vahideh;
Orman, Mehmet A.

Publication type:

Article

Case report: A case of classic hairy cell leukemia with CNS involvement treated with vemurafenib.

Published in:

Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2022.1100577

By:

Johnson, Anna E.;
Raju, Athul Raj;
Jacob, Aasems;
Hildebrandt, Gerhard C.

Publication type:

Article

Vemurafenib inhibits immune escape biomarker BCL2A1 by targeting PI3K/AKT signaling pathway to suppress breast cancer.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.906197

By:

Yalan Dai;
Liqiong Yang;
Sakandar, Abass;
Duoli Zhang;
Fukuan Du;
Xinyi Zhang;
Linglin Zou;
Yueshui Zhao;
Jigang Wang;
Zhenhua Zhang;
Xu Wu;
Mingxing Li;
Xiao Ling;
Lei Yu;
Lishu Dong;
Jing Shen;
Zhangang Xiao;
Qinglian Wen

Publication type:

Article

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 01, doi. 10.3389/fonc.2022.1022496

By:

Shaikh, Saba S.;
Yan Zang;
Hanmer, Janel;
Hong Wang;
Yan Lin;
Davar, Diwakar;
Zarour, Hassane M.;
Kirkwood, John M.;
Najjar, Yana G.

Publication type:

Article

Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.865656

By:

Hong, Ling;
Huang, Ping;
Zheng, Xiaochun;
Ye, Xiaolan;
Zhao, Hongying;
Wang, Jianwei;
Shao, Yanfei

Publication type:

Article

Adverse Effects of Vemurafenib on Skin Integrity: Hyperkeratosis and Skin Cancer Initiation Due to Altered MEK/ERK-Signaling and MMP Activity.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.827985

By:

Tham, Marius;
Stark, Hans-Jürgen;
Jauch, Anna;
Harwood, Catherine;
Pavez Lorie, Elizabeth;
Boukamp, Petra

Publication type:

Article

Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report.

Published in:

2022

By:

Wang, Ziyao;
He, Du;
Chen, Chen;
Liu, Xubao;
Ke, Nengwen

Publication type:

Case Study

Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.794216

By:

Li, Hongxia;
Wang, Yaping;
Su, Rina;
Jia, Yuchen;
Lai, Xiong;
Su, Huimin;
Fan, Yaochun;
Wang, Yuewu;
Xing, Wanjin;
Qin, Jianzhong

Publication type:

Article

Case Report: Early Association of Vemurafenib to Standard Chemotherapy in Multisystem Langerhans Cell Histiocytosis in a Newborn: Taking a Chance for a Better Outcome?

Published in:

2021

By:

Gaspari, Stefania;
Di Ruscio, Valentina;
Stocchi, Francesca;
Carta, Roberto;
Becilli, Marco;
De Ioris, Maria Antonietta

Publication type:

Case Study

Correction: Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.

Published in:

2024

By:

Hao, Jiaojiao;
Fan, Wenhua;
Li, Yizhuo;
Tang, Ranran;
Tian, Chunfang;
Yang, Qian;
Zhu, Tianhua;
Diao, Chaoliang;
Hu, Sheng;
Chen, Manyu;
Guo, Ping;
Long, Qian;
Zhang, Changlin;
Qin, Ge;
Yu, Wendan;
Chen, Miao;
Li, Liren;
Qin, Lijun;
Wang, Jingshu;
Zhang, Xiuping

Publication type:

Correction Notice

Molecular targeted therapy for progressive low-grade gliomas in children.

Published in:

Chinese Journal of Contemporary Pediatrics, 2025, v. 27, n. 6, p. 146, doi. 10.7499/j.issn.1008-8830.2410012

By:

SUN Yan-Ling;
LI Miao;
LIU Jing-Jing;
GAO Wen-Chao;
WU Yue-Fang;
WAN Lu-Lu;
REN Si-Qi;
DU Shu-Xu;
WU Wan-Shui;
SUN Li-Ming

Publication type:

Article

The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Published in:

Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04391-1

By:

Dummer, Reinhard;
Welti, Michèle;
Ramelyte, Egle

Publication type:

Article

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors.

Published in:

Molecules, 2023, v. 28, n. 13, p. 5273, doi. 10.3390/molecules28135273

By:

Żołek, Teresa;
Mazurek, Adam;
Grudzinski, Ireneusz P.

Publication type:

Article

Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines—An Isobolographic Analysis.

Published in:

Molecules, 2023, v. 28, n. 9, p. 3889, doi. 10.3390/molecules28093889

By:

Wróblewska-Łuczka, Paula;
Góralczyk, Agnieszka;
Łuszczki, Jarogniew J.

Publication type:

Article

Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4- b ]indol-3-one Derivatives as Potent Inhibitors of EGFR T790M /BRAF V600E Pathways.

Published in:

Molecules, 2023, v. 28, n. 3, p. 1269, doi. 10.3390/molecules28031269

By:

Al-Wahaibi, Lamya H.;
Mohammed, Anber F.;
Abdelrahman, Mostafa H.;
Trembleau, Laurent;
Youssif, Bahaa G. M.

Publication type:

Article

III 期恶性黑色素瘤患者术后辅助抗PD-1 vs 靶向治疗：中国多中心真实世界数据分.

Published in:

China Oncology, 2022, v. 32, n. 12, p. 1147, doi. 10.19401/j.cnki.1007-3639.2022.12.002

By:

李婷;
徐宇;
贾东东;
廖智超;
孙伟;
吴海啸;
任志午;
赵军;
邢汝维;
滕胜;
杨蕴;
陈勇;
李涛;
杨吉龙

Publication type:

Article

Vemurafenib for BRAF V600‐mutant Erdheim–Chester disease presenting with bilateral orbital involvement.

Published in:

2023

By:

Wang, Xiaomeng;
Cao, Jie;
Du, Weijiao;
Ma, Wenchao;
Meng, Bin;
Cao, Shui

Publication type:

Case Study

Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma.

Published in:

Clinical Case Reports, 2017, v. 5, n. 5, p. 694, doi. 10.1002/ccr3.911

By:

Matsuo, Toshihiko;
Yamasaki, Osamu

Publication type:

Article

Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.

Published in:

Thyroid, 2022, v. 32, n. 3, p. 273, doi. 10.1089/thy.2021.0565

By:

Tchekmedyian, Vatche;
Dunn, Lara;
Sherman, Eric;
Baxi, Shrujal S.;
Grewal, Ravinder K.;
Larson, Steven M.;
Pentlow, Keith S.;
Haque, Sofia;
Tuttle, R. Michael;
Sabra, Mona M.;
Fish, Stephanie;
Boucai, Laura;
Walters, Jamie;
Ghossein, Ronald A.;
Seshan, Venkatraman E.;
Knauf, Jeffrey A.;
Pfister, David G.;
Fagin, James A.;
Ho, Alan L.

Publication type:

Article

Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer.

Published in:

Journal of Cancer, 2023, v. 14, n. 9, p. 1592, doi. 10.7150/jca.83853

By:

Weike Ma;
Mengran Tian;
Linfei Hu;
Xianhui Ruan;
Wei Zhang;
Xiangqian Zheng;
Ming Gao

Publication type:

Article

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.

Published in:

Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-45798-8

By:

Hieken, Tina J.;
Nelson, Garth D.;
Flotte, Thomas J.;
Grewal, Eric P.;
Chen, Jun;
McWilliams, Robert R.;
Kottschade, Lisa A.;
Yang, Lu;
Domingo-Musibay, Evidio;
Dronca, Roxana S.;
Yan, Yiyi;
Markovic, Svetomir N.;
Dimou, Anastasios;
Montane, Heather N.;
Erskine, Courtney L.;
Piltin, Mara A.;
Price, Daniel L.;
Khariwala, Samir S.;
Hui, Jane;
Strand, Carrie A.

Publication type:

Article

Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis.

Published in:

Pediatric Hematology & Oncology, 2023, v. 40, n. 1, p. 86, doi. 10.1080/08880018.2022.2072986

By:

Mohapatra, Debabrata;
Gupta, Aditya Kumar;
Haldar, Partha;
Meena, Jagdish Prasad;
Tanwar, Pranay;
Seth, Rachna

Publication type:

Article

Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib.

Published in:

PLoS ONE, 2018, v. 13, n. 3, p. 1, doi. 10.1371/journal.pone.0195956

By:

Ladds, Marcus J. G. W.;
Pastor-Fernández, Andrés;
Popova, Gergana;
van Leeuwen, Ingeborg M. M.;
Eng, Kai Er;
Drummond, Catherine J.;
Johansson, Lars;
Svensson, Richard;
Westwood, Nicholas J.;
McCarthy, Anna R.;
Tholander, Fredrik;
Popa, Mihaela;
Lane, David P.;
McCormack, Emmet;
McInerney, Gerald M.;
Bhatia, Ravi;
Laín, Sonia

Publication type:

Article

17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.

Published in:

PLoS ONE, 2018, v. 13, n. 2, p. 1, doi. 10.1371/journal.pone.0191264

By:

Joshi, Sandeep S.;
Jiang, Shunlin;
Unni, Emmanual;
Goding, Stephen R.;
Fan, Tao;
Antony, Paul A.;
Hornyak, Thomas J.

Publication type:

Article

PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.

Published in:

Cell Communication & Signaling, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12964-022-00989-y

By:

Corrales, Eyleen;
Levit-Zerdoun, Ella;
Metzger, Patrick;
Mertes, Ralf;
Lehmann, Ariane;
Münch, Julia;
Lemke, Steffen;
Kowar, Silke;
Boerries, Melanie

Publication type:

Article

PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.

Published in:

Cell Communication & Signaling, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12964-022-00989-y

By:

Corrales, Eyleen;
Levit-Zerdoun, Ella;
Metzger, Patrick;
Mertes, Ralf;
Lehmann, Ariane;
Münch, Julia;
Lemke, Steffen;
Kowar, Silke;
Boerries, Melanie

Publication type:

Article

Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts.

Published in:

Cell Communication & Signaling, 2021, v. 19, n. 1, p. 1, doi. 10.1186/s12964-021-00801-3

By:

Corrales, Eyleen;
Levit-Zerdoun, Ella;
Metzger, Patrick;
Kowar, Silke;
Ku, Manching;
Brummer, Tilman;
Boerries, Melanie

Publication type:

Article

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells.

Published in:

Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1182853

By:

Guzzetti, Carlotta;
Corno, Cristina;
Vergani, Elisabetta;
Mirra, Luca;
Ciusani, Emilio;
Rodolfo, Monica;
Perego, Paola;
Beretta, Giovanni L.

Publication type:

Article

Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing BRAF<sup>V600E</sup>Mutated Erdheim-Chester Disease: A Case Report.

Published in:

2022

By:

Razanamahery, Jérôme;
Abdallahoui, Maroua;
Chabridon, Guillaume;
Fromont, Agnès;
Tarris, Georges;
Idbaih, Ahmed;
Comby, Pierre Olivier;
Godard, Francois;
Haroche, Julien;
Audia, Sylvain;
Bonnotte, Bernard

Publication type:

Case Study

Retraction Note: Utilization of solid in oil nanodispersion to prepare a topical vemurafenib as potential delivery system for skin melanoma.

Published in:

2024

By:

Almajidi, Yasir Q.;
Maraie, Nidhal K.;
Raauf, Ayad M. R.

Publication type:

Correction Notice

Utilization of solid in oil nanodispersion to prepare a topical vemurafenib as potential delivery system for skin melanoma.

Published in:

Applied Nanoscience, 2023, v. 13, n. 4, p. 2845, doi. 10.1007/s13204-021-02158-y

By:

Almajidi, Yasir Q.;
Maraie, Nidhal K.;
Raauf, Ayad M. R.

Publication type:

Article

Acquired and intrinsic resistance to vemurafenib in BRAF<sup>V600E</sup>‐driven melanoma brain metastases.

Published in:

FEBS Open Bio, 2024, v. 14, n. 1, p. 96, doi. 10.1002/2211-5463.13730

By:

Zhang, Ping;
Kuil, Laura Esmee;
Buil, Levi Conrad Maria;
Freriks, Stephan;
Beijnen, Jos Hendrik;
van Tellingen, Olaf;
de Gooijer, Mark Cornelis

Publication type:

Article

Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.

Published in:

2023

By:

Li, Qingqing

Publication type:

Case Study

Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications.

Published in:

Journal of Dermatological Treatment, 2022, v. 33, n. 3, p. 1368, doi. 10.1080/09546634.2020.1817838

By:

Mandel, Victor Desmond;
Medri, Matelda;
Manganoni, Ausilia Maria;
Pavoni, Laura;
De Rosa, Francesco;
Ribero, Simone;
Foca, Flavia;
Andreis, Daniele;
Mazzoni, Laura;
Magi, Serena;
Farnetani, Francesca;
Palla, Marco;
Ulivi, Paola;
Stanganelli, Ignazio

Publication type:

Article

miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.

Published in:

PLoS ONE, 2020, v. 15, n. 6, p. 1, doi. 10.1371/journal.pone.0234707

By:

Grzywa, Tomasz M.;
Klicka, Klaudia;
Paskal, Wiktor;
Dudkiewicz, Julia;
Wejman, Jarosław;
Pyzlak, Michał;
Włodarski, Paweł K.

Publication type:

Article

Resistance mechanism of the oncogenic β3‐αC deletion mutation in BRAF kinase to dabrafenib and vemurafenib revealed by molecular dynamics simulations and binding free energy calculations.

Published in:

Chemical Biology & Drug Design, 2019, v. 93, n. 2, p. 177, doi. 10.1111/cbdd.13399

By:

Niu, Yuzhen;
Zhang, Yan;
Yao, Xiaojun

Publication type:

Article

Neurodegeneration in patients with multisystem Langerhans cell histiocytosis treated with vemurafenib.

Published in:

British Journal of Haematology, 2024, v. 204, n. 6, p. 2508, doi. 10.1111/bjh.19483

By:

Trambusti, Irene;
Pegoraro, Francesco;
Gaspari, Stefania;
Dell'Acqua, Fabiola;
Cellini, Monica;
Trizzino, Antonino;
Tondo, Annalisa;
Perrone, Anna;
Coniglio, Maria Luisa;
Guerrini, Renzo;
Barba, Carmen;
Sieni, Elena

Publication type:

Article

Rapid exacerbation of malignant melanoma during short‐term discontinuation of vemurafenib.

Published in:

2018

By:

Saito, Ryo;
Iwamoto, Kazumasa;
Tanaka, Yurie;
Kawai, Mikio;
Hide, Michihiro

Publication type:

Case Study

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib.

Published in:

Biology (2079-7737), 2023, v. 12, n. 4, p. 608, doi. 10.3390/biology12040608

By:

Car, Iris;
Dittmann, Antje;
Klobučar, Marko;
Grbčić, Petra;
Kraljević Pavelić, Sandra;
Sedić, Mirela

Publication type:

Article

Novel Synergistic Anti-Enteroviral Drug Combinations.

Published in:

Viruses (1999-4915), 2022, v. 14, n. 9, p. 1866, doi. 10.3390/v14091866

By:

Ianevski, Aleksandr;
Zusinaite, Eva;
Tenson, Tanel;
Oksenych, Valentyn;
Wang, Wei;
Afset, Jan Egil;
Bjørås, Magnar;
Kainov, Denis E.

Publication type:

Article

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer.

Published in:

Thyroid Research, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13044-023-00147-7

By:

Lang, Matthias;
Longerich, Thomas;
Anamaterou, Chrysanthi

Publication type:

Article

MitoCur‐1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14.

Published in:

Pigment Cell & Melanoma Research, 2024, v. 37, n. 2, p. 316, doi. 10.1111/pcmr.13150

By:

Li, Gege;
Zhou, Changlong;
Wang, Lu;
Zheng, Yalong;
Zhou, Bo;
Li, Guoyan;
Ma, Zhongyu;
Sun, Peng;
Deng, Yuantao;
Su, Li;
Wang, Junling;
Cui, Hongmei

Publication type:

Article